Tenax Therapeutics Competitors and Similar CompaniesClear all

Tenax Therapeutics's competitors and similar companies include Mankind Pharma, Alembic Pharmaceuticals, UCB and Genentech.

	Tenax Therapeutics Tenax Therapeutics, formerly Oxygen Biotherapeutics, is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care patients.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
Founding Date	Founding Date 1967	Founding Date 1995	Founding Date 2010	Founding Date 1928	Founding Date 1976
Type	Type Public	Type Private	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Morrisville, US HQ	Locations New Delhi, IN HQ	Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more
Employees	Employees 929% increase	Employees 16,2532% increase	Employees 14,858	Employees 9,052	Employees 18,077
Valuation ($)	Valuation ($) 15.6 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 34.3 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₹73.4b (FY, 2026)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹19.8b (FY, 2026)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ₹54.1b (FY, 2026)	Gross profit €7.2b (FY, 2025)	Gross profit N/A
Net income	Net income ($52.6m) (FY, 2025)	Net income N/A	Net income ₹6.7b (FY, 2026)	Net income €1.6b (FY, 2025)	Net income N/A
Operating ⚠
Phase III Trials Products	Phase III Trials Products 1 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 41 (Jul, 2025)